Risk-based Monitoring of Clinical Trials: An Integrative Approach.

PURPOSE Clinical trial monitoring is an essential component of drug development aimed at safeguarding subject safety, data quality, and protocol compliance by focusing sponsor oversight on the most important aspects of study conduct. In recent years, regulatory agencies, industry consortia, and nonprofit collaborations between industry and regulators, such as TransCelerate and International Committee for Harmonization, have been advocating a new, risk-based approach to monitoring clinical trials that places increased emphasis on critical data and processes and encourages greater use of centralized monitoring. However, how best to implement risk-based monitoring (RBM) remains unclear and subject to wide variations in tools and methodologies. The nonprescriptive nature of the regulatory guidelines, coupled with limitations in software technology, challenges in operationalization, and lack of robust evidence of superior outcomes, have hindered its widespread adoption. METHODS We describe a holistic solution that combines convenient access to data, advanced analytics, and seamless integration with established technology infrastructure to enable comprehensive assessment and mitigation of risk at the study, site, and subject level. FINDINGS Using data from completed RBM studies carried out in the last 4 years, we demonstrate that our implementation of RBM improves the efficiency and effectiveness of the clinical oversight process as measured on various quality, timeline, and cost dimensions. IMPLICATIONS These results provide strong evidence that our RBM methodology can significantly improve the clinical oversight process and do so at a lower cost through more intelligent deployment of monitoring resources to the sites that need the most attention.

[1]  Dimitris K. Agrafiotis,et al.  Quantifying and visualizing site performance in clinical trials , 2018, Contemporary clinical trials communications.

[2]  Jeremy Kolpak,et al.  Clinical Case: Enhancing medical monitoring with visualization and analytics , 2012, 2012 IEEE International Conference on Bioinformatics and Biomedicine.

[3]  Catrin Tudur Smith,et al.  The Value of Source Data Verification in a Cancer Clinical Trial , 2012, PloS one.

[4]  Xiang Yao,et al.  Advanced Biological and Chemical Discovery (ABCD): Centralizing Discovery Knowledge in an Inherently Decentralized World , 2007, J. Chem. Inf. Model..

[5]  Jules T. Mitchel,et al.  Evaluation of Data Entry Errors and Data Changes to an Electronic Data Capture Clinical Trial Database , 2011, Drug information journal.

[6]  Andrew P. Grieve Source Data Verification by Statistical Sampling: Issues in Implementation , 2012 .

[7]  D. Gill,et al.  Re-inventing clinical trials through TransCelerate , 2014, Nature Reviews Drug Discovery.

[8]  Sheena McCormack,et al.  The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial , 2012, Clinical trials.

[9]  Michael Farnum,et al.  Broadening access to electronic healthcare databases , 2010, Nature Reviews Drug Discovery.

[10]  Yong Joong Kim,et al.  Extended Risk-Based Monitoring Model, On-Demand Query-Driven Source Data Verification, and Their Economic Impact on Clinical Trial Operations , 2016, Therapeutic innovation & regulatory science.